3 completed, 1 terminated. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Terminated 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
Follow Advancell - Advanced In Vitro Cell Technologies, S.A.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GFM-Acadesine: A Phase I-II Trial of Acadesine ACADESINE 140mg/kg/d, ACADESINE 210mg/kg/d, ACADESINE 315mg/kg/d - SMD | Phase 1 / Phase 2 | Terminated | Groupe Francophone des Myelodysplasies | 5 | 2013-06-01 | 2016-11-08 |
| A Phase IIa Study of NT-KO-003 for Multiple Sclerosis NT-KO-003 - Relapsing Remitting Multiple Sclerosis | Phase 2 | Completed | Neurotec Pharma | 99 | 2011-06-01 | 2014-03-18 |
| Safety and Efficacy Placebo Controlled Study of ATH008 Cream in PPES Patients Secondary to Capecitabine ATH008 - Palmar-Plantar Erythrodysesthesia Syndrome | Phase 2 | Completed | Advancell - Advanced In Vitro Cell Technologies, S.A. | 122 | 2011-02-01 | 2014-01-30 |
| Safety and Tolerability Open Label Dose Escalation Study of Acadesine in B-CLL Patients Acadesine - Leukemia, B-Cell, Chronic | Phase 1 / Phase 2 | Completed | Advancell - Advanced In Vitro Cell Technologies, S.A. | 40 | 2007-12-01 | 2011-05-10 |
Hand-Foot Syndrome (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Multiple Sclerosis, Relapsing-Remitting (1)
acadesine (2)
Spain (3) · Belgium (2) · France (2) · Germany (2) · Italy (1)
Dr. A. Awada (1) · Eric Van Den Neste, MD (1) · Pablo Villoslada, MD PhD (1) · Pierre Fenaux, MD (1) · Thomas Cluzeau, MD (1)